ATE521629T1 - Matrixmetalloproteinase-11-impfstoff - Google Patents

Matrixmetalloproteinase-11-impfstoff

Info

Publication number
ATE521629T1
ATE521629T1 AT06792355T AT06792355T ATE521629T1 AT E521629 T1 ATE521629 T1 AT E521629T1 AT 06792355 T AT06792355 T AT 06792355T AT 06792355 T AT06792355 T AT 06792355T AT E521629 T1 ATE521629 T1 AT E521629T1
Authority
AT
Austria
Prior art keywords
mmp
compositions
terminus
linked
immunoenhancing element
Prior art date
Application number
AT06792355T
Other languages
English (en)
Inventor
Luigi Aurisicchio
Monica Nicola La
Gennaro Ciliberto
Domenico Lazzaro
Federica Mori
Daniela Peruzzi
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Application granted granted Critical
Publication of ATE521629T1 publication Critical patent/ATE521629T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6416—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT06792355T 2005-10-07 2006-10-03 Matrixmetalloproteinase-11-impfstoff ATE521629T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72449805P 2005-10-07 2005-10-07
PCT/EP2006/009536 WO2007042169A2 (en) 2005-10-07 2006-10-03 Matrix metalloproteinase 11 vaccine

Publications (1)

Publication Number Publication Date
ATE521629T1 true ATE521629T1 (de) 2011-09-15

Family

ID=37451271

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06792355T ATE521629T1 (de) 2005-10-07 2006-10-03 Matrixmetalloproteinase-11-impfstoff

Country Status (9)

Country Link
US (2) US8106176B2 (de)
EP (1) EP1934246B8 (de)
JP (1) JP5361386B2 (de)
CN (1) CN101365715B (de)
AT (1) ATE521629T1 (de)
AU (1) AU2006301582B2 (de)
CA (1) CA2623531C (de)
ES (1) ES2370040T3 (de)
WO (1) WO2007042169A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI626945B (zh) 2008-08-14 2018-06-21 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
EP2568044B1 (de) * 2008-09-29 2015-04-08 The Trustees of The University of Pennsylvania Auf Tumorgefässmarker gerichtete Impfstoffe
JP5912078B2 (ja) 2009-06-08 2016-04-27 アクセルロン ファーマ， インコーポレイテッド 熱発生性脂肪細胞を増加させるための方法
CN102655872B (zh) * 2009-08-13 2016-01-20 阿塞勒隆制药公司 Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平
CN107028886A (zh) * 2009-11-04 2017-08-11 不列颠哥伦比亚大学 含有核酸的脂质粒子及相关的方法
US20140328759A1 (en) 2011-10-25 2014-11-06 The University Of British Columbia Limit size lipid nanoparticles and related methods
WO2014172045A1 (en) 2013-03-15 2014-10-23 The University Of British Columbia Lipid nanoparticles for transfection and related methods
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
FI3273986T3 (fi) 2015-03-27 2024-02-07 Immatics Biotechnologies Gmbh Uusia peptidejä ja peptidien yhdistelmiä käytettäväksi immunoterapiassa eri syöpiä vastaan
CN110418648B (zh) * 2017-02-22 2023-09-08 丁恩雨 一种编码人GM-CSF与多串连表位融合的mRNA癌症疫苗
JP2022552260A (ja) * 2019-10-08 2022-12-15 エクスハウラ リミテッド 眼治療のための組成物および方法
US20240199725A1 (en) 2021-04-16 2024-06-20 Korea University Research And Business Foundation Human antibody targeting covid-19 virus
GB202117583D0 (en) * 2021-12-06 2022-01-19 Cambridge Entpr Ltd Protein expression
CN116590263A (zh) * 2023-07-02 2023-08-15 广州庆毅生物医药科技有限公司 一种重组蛋白、单克隆抗体及其检测试剂盒和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78775A (en) 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
GB9112553D0 (en) 1991-06-11 1991-07-31 Wellcome Found Fusion proteins
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
CA2255539C (en) * 1996-05-23 2005-09-27 Xoma Corporation Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma
US6114148C1 (en) * 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
HUP0201019A2 (en) 1999-04-26 2002-08-28 Leuven K U Res & Dev Synthetic gene for expressing active retroviral protein in eukaryotes
AU7865900A (en) * 1999-10-08 2001-04-23 Active Biotech Ab AB5 toxin B subunit mutants with altered chemical conjugation characteristics
GB9930768D0 (en) * 1999-12-29 2000-02-16 Pfizer Ltd Composition
AU2001294562B2 (en) 2000-09-15 2007-05-24 Merck & Co., Inc. Enhanced First Generation Adenovirus Vaccines Expressing Codon Optimized HIV1-Gag, Pol, Nef and Modifications
US20040110152A1 (en) 2002-12-10 2004-06-10 Isis Pharmaceuticals Inc. Modulation of matrix metalloproteinase 11 expression
GB0321615D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
SG146662A1 (en) * 2003-10-10 2008-10-30 Powderject Vaccines Inc Method
ES2387850T3 (es) 2004-02-11 2012-10-02 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. Proteína de fusión al antígeno carcinoembrionario y sus usos

Also Published As

Publication number Publication date
JP5361386B2 (ja) 2013-12-04
AU2006301582B2 (en) 2011-10-13
CN101365715B (zh) 2013-03-27
ES2370040T3 (es) 2011-12-12
WO2007042169A2 (en) 2007-04-19
US20090155298A1 (en) 2009-06-18
CA2623531A1 (en) 2007-04-19
US8492522B2 (en) 2013-07-23
EP1934246A2 (de) 2008-06-25
AU2006301582A1 (en) 2007-04-19
CN101365715A (zh) 2009-02-11
US8106176B2 (en) 2012-01-31
JP2009509553A (ja) 2009-03-12
EP1934246B1 (de) 2011-08-24
US20120177679A1 (en) 2012-07-12
CA2623531C (en) 2013-12-10
EP1934246B8 (de) 2012-02-08
WO2007042169A3 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
EP1934246B8 (de) Matrixmetalloproteinase-11-impfstoff
PH12023550266A1 (en) Anti-ceacam5 antibodies and conjugates and uses thereof
BR0113491A (pt) Polinucleotìdeo e polipeptìdeo isolados, vetor de expressão, célula hospedeira, proteìna de fusão, métodos para estimular e/ou expandir células t especìficas para uma protéina de tumor, para estimular uma resposta imune em um paciente, para o tratamento de um câncer em um paciente e para inibir o desenvolvimento de um câncer em um paciente, população de célula t isolada, composição, e, uso de um componente.
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
DK1549353T3 (da) Anvendelse af alfa(1,3)galactosyltransferaseudtrykkende allogene tumorceller til vaccination mod tumorer
BRPI0509201A (pt) agentes de acoplamento de receptor e usos terapêuticos destes
MX2017014083A (es) Polipeptido de fusion anti-cancer.
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
MX390894B (es) Polipéptido de fusión anti-cáncer.
TNSN07387A1 (en) C.perfringens alpha toxoid vaccine
BR0107643A (pt) Composições e processos para a terapia e diagnóstico de c ncer de próstata
DE602006019446D1 (de) An humane leukozytenantigen-(hla-)klasse-i- oder ii-moleküle bindende tumorassoziierte peptide und damit im zusammenhang stehender impfstoff gegen krebs
DK1922335T3 (da) Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler
WO2002089747A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
EA200970607A1 (ru) Универсальная вакцина из опухолевых клеток для противораковой терапии и профилактического использования
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
AR031250A1 (es) Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon
BR112021025699A2 (pt) Anticorpos anti-mesotelina e imunoconjugados dos mesmos
CL2022001727A1 (es) Anticuerpos específicos contra la claudina 18.2 tumoral
ES2187568T3 (es) Vacuna viva para el tratamiento de enfermedades tumorales.
PH12022551078A1 (en) Combination therapy to treat brain cancer
NO20055209D0 (no) Peptabody for cancerbehandling
WO2008036973A3 (en) Modulating regulatory t cell activity via interleukin 35
WO2001077168A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
DK1354054T3 (da) Polypeptider der kan binde til CD64, og som omfatter en eller flere heterologe T-celle-epitoper, samt anvendelser deraf

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties